By Dr Nicola Davies
Rett syndrome (RTT) is a rare neurodevelopmental disorder, affecting about 1 in 10,000 girls born each year.1 Present at conception, RTT leads to major developmental regression around 6-30 months after birth, with patients typically becoming withdrawn and losing acquired social and motor skills.
Repetitive behaviors, respiratory phenotypes and autonomic dysfunction are also hallmarks of the disease. As an X-linked dominant disorder, males are rarely affected by RTT and if they are, they seldom survive into adulthood.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze